Daré Bioscience (NASDAQ:DARE) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $12.00 price objective on the biotechnology company’s stock.

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Price Performance

NASDAQ:DARE traded down $0.36 during trading hours on Friday, hitting $3.21. The stock had a trading volume of 103,013 shares, compared to its average volume of 47,472. The company has a 50 day simple moving average of $3.56 and a two-hundred day simple moving average of $3.92. The firm has a market capitalization of $27.45 million, a price-to-earnings ratio of -2.86 and a beta of 1.34. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56.

Hedge Funds Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.